With multi-indication PBS listing widening immunotherapy access for advanced and metastatic cancers, ‘clinical judgement and discretion’ takes on new meaning for oncologists. Watch again as an expert panel shares what the evidence says about immunotherapy-sensitive tumours and discusses how to position IO within the current treatment armamentarium.
Click on chapters below to view topics
Chapter 1: IO sensitive indications for common cancers
Chapter 2: IO sensitive indications for rare cancers
Chapter 3: Are biomarkers necessary for pan-cancer IO prescribing?
Chapter 4: Omico real world data and implications of pan-tumour IO funding
Developed in partnership with MOGA
Hosted by Associate Professor Jenny Liu
Medical Oncologist and Translational Lead of the Early Phase Trials Unit, The Kinghorn Cancer Centre, St Vincent’s Hospital, Sydney; Executive Member, Medical Oncology Group of Australia (MOGA).
PANEL
Professor Razelle Kurzrock. Director, Center for Precision Oncology and Rare Cancers; Linda T. and John A. Mellowes Endowed Chair of Precision Oncology, MCW Cancer Center and Linda T. and John A. Mellowes Center for Genomic Sciences and Precision Medicine; Founding Director, Michels Rare Cancers Research Laboratories, Froedtert and Medical College of Wisconsin; Professor of Medicine, Medical College of Wisconsin.
Professor David Thomas. Director, Centre for Molecular Oncology, School of Biomedical Sciences, UNSW; Chief Science and Strategy Officer, OMICO (Australian Genomic Cancer Medicine Centre).
Dr Gregory Gaughran. Medical Oncologist, Melbourne, Research Fellow Monash/UNSW; Molecular Oncologist, Omico/CASP, Honorary Fellow FCC Monash Health.
For more information, please contact [email protected]
Thank you to our partner
Sponsored by
These webinars are supported by unrestricted educational grants and created independently by the Medical Oncology Group of Australia (MOGA) in collaboration with the limbic. All content is selected by the participants and all views expressed are those of the participants only.